Dataset Information

Based on untargeted metabolomics and metagenomics: a study on the mechanism of Miao ethnomedicine Zingiber mioga (Thunb.) Rosc. in treating slow transit constipation

ABSTRACT:

A rat model of slow transit constipation (STC) was induced by loperamide hydro-chloride to explore the therapeutic mechanism of Zingiber mioga (Thunb.) Rosc. (RH) using integrated metabolomic and metagenomic approaches. Thirty-six Sprague–Dawley (SD) rats were randomly assigned to 6 groups (n = 6): the con-trol group, model group, mosapride-positive control group (2 mg kg−1), and RH low- (1,350 mg kg−1), medium- (2,700 mg kg−1), and high-dose (3,400 mg kg−1) groups. The STC model was established by intragastric administration of lop-eramide hydrochloride (5 mg/kg) for 35 consecutive days, with simultaneous drug intervention. Serum levels of substance P (SP), motilin (MTL), and gastrin (GAS) were quantified; colonic pathological sections were prepared; and serum untargeted metabolomics and fecal metagenomics analyses were conducted. Key findings demonstrated that RH significantly decreased serum SP levels while elevating MTL and GAS levels in STC rats, attenuated colonic pathological lesions, and increased intestinal propulsion rate. Serum metabolomics analysis identified 15 differential metabolites, which were primarily involved in nitrogen metabolism, neuroactive ligand-receptor interaction, and amino acid metabo-lism. Fecal metagenomics analysis revealed that RH restored the Eubacteriales/ Lachnospirales ratio and increased the relative abundance of probiotic genera (e.g., Ruminococcus sp., Eubacterium sp.). In conclusion, RH exerts laxative effects in STC rats by regulating gastrointestinal hormones, mitigating colonic injury, and accelerating intestinal peristalsis. These effects may be mediated by ameliorating amino acid and nitrogen metabolic disorders and modulating gut microbiota composition.

INSTRUMENT(S): Liquid Chromatography MS - negative - reverse-phase, Liquid Chromatography MS - positive - reverse-phase

PROVIDER: MTBLS13888 | MetaboLights | 2026-02-11

REPOSITORIES: MetaboLights

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	a_MTBLS13888_LC-MS_negative_reverse-phase_metabolite_profiling.txt	Txt
	a_MTBLS13888_LC-MS_positive_reverse-phase_metabolite_profiling.txt	Txt
	i_Investigation.txt	Txt
	m_MTBLS13888_LC-MS_negative_reverse-phase_metabolite_profiling_v2_maf.tsv	Tabular
	m_MTBLS13888_LC-MS_positive_reverse-phase_metabolite_profiling_v2_maf.tsv	Tabular

Items per page:

1 - 5 of 6

Similar Datasets

Project description:Nafion byproduct 2 (NBP2; CAS: 749836-20-2; Product #: 6164-3-3J; Lot: 512400; SynQuest Laboratories Alachua, FL, USA) is a polyfluoroalkyl ether sulfonic acid that was recently detected in surface water, drinking water, and human serum samples from monitoring studies in North Carolina, USA. We orally exposed pregnant Sprague-Dawley rats to NBP2 from gestation day (GD) 14–18 (0.1–30 mg/kg/d), GD17-21, and GD8 to postnatal day (PND) 2 (0.3–30 mg/kg/d) to characterize maternal, fetal, and postnatal effects. GD14-18 exposures were also conducted with perfluorooctane sulfonate (PFOS) for comparison to NBP2, as well as data previously published for hexafluoropropylene oxide-dimer acid (HFPO-DA or GenX). NBP2 produced stillbirth (30 mg/kg), reduced pup survival shortly after birth (10 mg/kg), and reduced pup body weight (10 mg/kg). Histopathological evaluation identified reduced glycogen stores in newborn pup livers and hepatocyte hypertrophy in maternal livers at ≥ 10 mg/kg. Exposure to NBP2 from GD14-18 reduced maternal serum total T3 and cholesterol concentrations (30 mg/kg). Maternal, fetal, and neonatal liver gene expression was investigated using RT-qPCR pathway arrays, while maternal and fetal livers were also analyzed using TempO-Seq transcriptomic profiling. Overall, there was limited alteration of genes in maternal or F1 livers from NBP2 exposure with significant changes mostly occurring in the top dose group (30 mg/kg) associated with lipid and carbohydrate metabolism. Metabolomic profiling indicated elevated maternal bile acids for NBP2, but not HFPO-DA or PFOS, while all three reduced 3-indolepropionic acid. Maternal and fetal serum and liver NBP2 concentrations were similar to PFOS, but ∼10–30-fold greater than HFPO-DA concentrations at a given maternal oral dose. NBP2 is a developmental toxicant in the rat, producing neonatal mortality, reduced pup body weight, reduced pup liver glycogen, reduced maternal thyroid hormones, and altered maternal and offspring lipid and carbohydrate metabolism similar to other studied PFAS, with oral toxicity for pup loss that is slightly less potent than PFOS but more potent than HFPO-DA.

Dataset Information

Based on untargeted metabolomics and metagenomics: a study on the mechanism of Miao ethnomedicine Zingiber mioga (Thunb.) Rosc. in treating slow transit constipation

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets